London, England, Jun 23, 2021 – CyberLiver Ltd, a MedTech startup re-inventing liver care through its new digital therapeutics’ solutions for the treatment of advanced liver disease, today announced poster and oral presentations for The International Liver Congress 2021. The poster highlights data on effectiveness of alerting to new decompensation events not leading to readmissions with 85% patient engagement.

Prof. Raj Mookerjee, Professor of Translational Hepatology in Hepatology at Royal Free Hospital and UCL and Chief Investigator of the trial commented: “I am delighted to have the opportunity to share our early findings of the potential for a Digital Therapeutics solution such as CirrhoCare, to manage patients with decompensated cirrhosis at The International Liver Congress 2021. The data from the clinical study conducted between Jun 2020 and Jan 2021 at Royal Free London NHS Trust, suggests early indications that CirrhoCare as a cirrhosis management solution can facilitate early detection of decompensated cirrhosis events, allowing timely remote intervention, to reduce hospital admissions and hospital stay days, and improve the quality of life of patients.”

Mr. Ravi Kumar, CEO & Founder, CyberLiver, commented: “The data from the clinical study supported by funding from Innovate UK, shows a great potential for CirrhoCare to significantly reduce mortality and improve the quality of life of patients with decompensated cirrhosis though early detection and intervention of decompensated events, while simultaneously empowering people to access care as they need it. The results will pave the way for CirrhoCare to progress to the next stage of clinical trials and regulatory pathway.”

About CyberLiver: CyberLiver is a MedTech company that focuses on delivering novel digital therapeutics solutions for Liver Care using innovative technology, based out of London, England, UK. For more information visit www.cyberliver.com

Contact:

CyberLiver Limited

Ravi Kumar, CEO

[email protected]

Phone: +44 7970002610